Search

Your search keyword '"Schettino, C"' showing total 149 results

Search Constraints

Start Over You searched for: Author "Schettino, C" Remove constraint Author: "Schettino, C"
149 results on '"Schettino, C"'

Search Results

1. Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients

2. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy

6. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

8. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

9. Evaluation of angiogenesis-related genes as prognostic biomarkers of bevacizumab treated ovarian cancer patients: Results from the phase iv mito16a/mango ov-2 translational study

10. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

12. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

13. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

14. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial

15. Evaluation of angiogenesis-related genes as prognostic biomarkers of bevacizumab treated ovarian cancer patients: Results from the phase iv mito16a/mango ov-2 translational study

17. 167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials

20. Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study

22. Adherence to anti-Parkinson drug therapy in the 'REASON' sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the 'Morisky Medical Adherence Scale-8 items'

23. Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study

24. Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study

27. Atypical Stüve-Wiedemann syndrome (STWS) masquerating as Cold-induced sweating syndrome (CISS): a patient homozygous for a LIFR mutation followed for 30 years

28. Optimization of Sediment Washing Technology for Remediation of Heavy Metal Contaminated Sediments

30. Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study

33. The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

39. Nanotechnologies for Conservation of Cultural Heritage:  Paper and Canvas Deacidification

41. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

42. Evaluation of angiogenesis-related genes as prognostic biomarkers of bevacizumab treated ovarian cancer patients: Results from the phase iv mito16a/mango ov-2 translational study

43. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

44. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

45. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

46. A disciplina fiscal na Europa da 'regra dos 3%' ao output gap

47. Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

48. The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

49. The use of xenograft models for the selection of cancer treatments with the EGFR as an example

50. The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources